Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
2.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349–1357.
3.
SacksFMPfefferMAMoyeLA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335(14):1001–1009.
4.
ShepherdJCobbeSMFordI. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–1307.
5.
RidkerPMDanielsonEFonsecaFA; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
GadarlaMKearnsAKThompsonPD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008;101(12):1747–1748.
8.
Pablos-MendezABarrRGSheaS. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279(3):222–225.
9.
BruckertEHayemGDejagerSYauCBegaudB. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–414.
10.
PhillipsPSHaasRHBannykhS. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137(7):581–585.
11.
StroesESThompsonPDCorsiniA; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022.
12.
BanachMRizzoMTothPP. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.
13.
ChamSEvansMADenenbergJOGolombBA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541–553.
14.
ChatzizisisYSKoskinasKCMisirliGVaklavasCHatzitoliosAGiannoglouGD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33(3):171–187.
15.
LinkEParishSArmitageJ. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359(8):789–799.
16.
GhatakAFaheemOThompsonPD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210(2):337–343.
17.
WilkeRARamseyLBJohnsonSG. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92(1):112–117.
18.
CarrDFO’MearaHJorgensenAL. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther. 2013;94(6):695–701.
19.
CanestaroWJAustinMAThummelKE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med. 2014;16(11):810–819.
20.
RamseyLBJohnsonSGCaudleKE. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423–428.
21.
TalamehJAKitzmillerJP. Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants. J Pharmacogenomics Pharmacoproteomics. 2014;5(2). Pii:128.
22.
Michalska-KasiczakMSahebkarAMikhailidisDP. Analysis of vitamin D levels in patients with and without statin-associated myalgia—a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111–116.
23.
HarperCRJacobsonTA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007;18(4):401–408.
24.
GuptaAThompsonPD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215(1):23–29.
25.
CasoGKellyPMcNurlanMALawsonWE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409–1412.
26.
BanachMSerbanCSahebkarA. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24–34.
27.
BanachMMikhailidisDP; Lipid and Blood Pressure Meta-analysis Collaboration Group. In reply—Coenzyme Q10 and statin-induced myopathy. Mayo Clin Proc. 2015;90(3):420–421.
28.
BertaEHarangiMZsirosNNagyEVParaghGBodorM. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. Pharmazie. 2014;69(6):420–423.
29.
CappolaARLadensonPW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003;88(6):2438–2444.
30.
LandoHMBurmanKD. Two cases of statin-induced myopathy caused by induced hypothyroidism. Endocr Pract. 2008;14(6):726–731.
31.
Hamilton-CraigI. Statin-associated myopathy. Med J Aust. 2001;175(9):486–489.
